Monday, January 20, 2020

Topic Discussion: Hypertension and TMA- chicken or the egg?

A recent discussion on twitter and ASN Communities has sparked this age old battle if HTN related TMA exists? Some believe that TMA is the initial insult and that leads to endothelial damage and HTN is a symptom and not the disease. Some believe that HTN is the start - leading to sheer stress and endothelial damage and in severe cases-- TMA

Check out the amazing twitter discussion by TMA experts on this topic.
What i found was this amazing image
Image
As one can see in this image- with some data existing on this - that malignant HTN can lead to endothelial dysfunction and some complement activation but not as severe as aHUS.

So if HTN does cause TMA, how does one distinguish that from a complement mediated TMA or aHUS? What if we are missing a mutation or an antibody that we haven't discovered.

1) Kidney biopsy cannot distinguish HTN induced TMA from complement mediated TMA 2) C3 being low is more valuable for an over active complement cascade compared to C5b-9 as even HTN can cause that to be elevated
3)) Doing a fundus exam can help significantly- there is no value in genetic testing in grade 3/4 retinopathy and especially with DBP>130mm Hg 4) No value in genetic testing in those that have a good response to bp control and eventually stabilized kidney function.
5) Ongoing TMA despite bp control and recovering of renal function- likely is then not HTN mediated and additional complement testing should be done.

Tuesday, December 31, 2019

Concept map: Immune check point inhibitors and the Kidney



This is the summary of the renal effects of ICI therapy on the kidney ( as of Dec 2019). This might change as we learn more and more about these agents.

Thursday, December 19, 2019

Coming in May of 2020- A glomerular disease conference at Northwell

An Update on Glomerular Diseases, 2020
#northwellGN2020
Saturday, May 2, 2020


7:30am to 6:00pm
North Shore University Hospital
300 Community Drive
Manhasset, New York  11030
@hofstrakidney
Registration information to follow in few weeks 

Visiting Faculty
Gerald Appel, MD
Barry I. Freedman, MD
Richard Glassock, MD
Duruvu Geetha, MBBS
Brad H. Rovin, MD
Shikha Wadhwani, MD,MS

 
Northwell Health Faculty
Vanesa Bijol, MD*
Steven Fishbane, MD*
Kenar D. Jhaveri, MD*
Hitesh H Shah, MD
Purva Sharma, MD *
Nupur N. Uppal, MD

* Course Directors

 

















8:00AM                            Introduction Kenar D. Jhaveri, MD 
8:15AM                            Membranous Nephropathy in the PLA2R era Richard Glassock, MD,
9:00 AM                           Thrombotic Microangiopathies, A novel approach, Vanesa Bijol, MD
9:45 AM                           ANCA and Anti GBM disease in 2020- some old and some new, Duruvu Geetha, MBBS
10:15AM                          Break and exhibits
10:30 AM                         SGLT-2 inhibitors, diabetic nephropathy and beyond!! Nupur N Uppal, MD
11:10 AM                         Treating the right clone- Paraproteinemias Kenar D. Jhaveri, MD
12:00 PM                         Lunch and exhibits
1:00 PM                            MPGN, C3GN..a paradigm shift. Shikha Wadhwani, MD,MS
1:40 PM                            Drugs, Chemo, Toxins—and the glomeruli.  Hitesh H Shah, MD
2:15 PM                            IgA Nephropathy- treat or not to treat. Gerald Appel, MD
3:00 PM                            Podocytopathies, Clinical approach and treatment.  Purva Sharma, MD
3:40 PM                            Treatment of Refractory Lupus Nephritis, Brad H. Rovin, MD
4:15 PM                            Break and Exhibit
4:30 PM                            Did you find my gene for the glomerular disease??. Barry I. Freedman, MD
5:00PM                             Case Studies in Glomerular diseases, Vanesa Bijol, MD Purva Sharma ,MD and Kenar D. Jhaveri,MD

Tuesday, November 26, 2019

Concept Map: Thiazide induced hyponatremias(TAH)


We see this form of hyponatremia in several cases, but recently there has been some newer findings on the mechanisms of TAH(*).  In one study published in JCI in 2017, Ware et al showed that there is a subset of patients with a genetic baseline( SLCO2A1 mutation) decrease in prostaglandin(PGE) transport activity which then becomes a risk factor for TAH.  So these patients have increased urinary PGE2 and low AVP levels leading to a pure "nephrogenic" cause of tubular water absorption and dilution hyponatremia. PGE2 is critical in insertion and removal of AQP2 channels in the apical membrane. Increased PGE2 signaling leads to insertion of AQP2 channels into membrane and increase water absorption in an ADH independent manner. This is fascinating. Perhaps then mechanism in NSAIDS as well?
Check out this amazing review in AJKD on this topic. 

Friday, November 22, 2019

Topic Discussion: Zytiga (Abiraterone) induced hypernatremia, and HTN


Zytiga (Abiraterone) is a hormonal chemotherapy agent used to treat prostate cancer. It selectively and irreversibly inhibits CYP17 (17 alpha-hydroxylase/C17,20-lyase), an enzyme required for androgen biosynthesis which is expressed in testicular, adrenal, and prostatic tumor tissues. Inhibits the formation of the testosterone precursors dehydroepiandrosterone (DHEA) and androstenedione.

Interestingly. it has a high rate of hypernatremia as a known renal complication. In several studies, hypernatremia (33%), hypokalemia (17% to 30%) were reported as known complications. Why? It is postulated that it can increase mineralocorticoids due to CYP17 inhibition may result in hypertension, hypokalemia, and fluid retention (including grade 3 and 4 events) and perhaps some component of hypernatremia as well- almost like a Cushing's state. Per package insert, concomitant administration with corticosteroids reduces the incidence and severity of these adverse events.

In the LATITUDE trial, which used prednisone 5 mg daily in combination with 1000 mg abiraterone acetate daily, grades 3-4 hypokalemia were detected in 10% of patients on the zytiga arm and 1% of patients on the placebo arm, grades 3-4 hypertension were observed in 20% of patients on the zytiga arm and 10% of patients on the placebo arm. Grades 3-4 fluid retention occurred in 1% of patients each arm.

It is recommended that patients get monitored for hypertension, hypokalemia, and fluid retention at least once a month. Treatment of hypertension is recommended, choice of drug is not defined.
This is an interesting toxicity that as nephrologist seeing prostate cancer with CKD and perhaps new onset hypertension, hypokalemia or hypernatremia should consider in the differential diagnosis.

Friday, November 15, 2019

In the News: Selinexor induced hyponatremia

A new drug just got approved for treatment for myeloma. It is called selinexor. The correct localization of molecules between nucleus and cytoplasm is fundamental for cellular homeostasis and is controlled by a bidirectional transport system. Exportin 1 (XPO1) regulates the passage of numerous cancer-related proteins. The development of a novel class of antitumor agents, known as selective inhibitors of nuclear export (SINEs) have shown good results in studies and clinical trials in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia, sarcomas, and gastric cancer. Selinexor is one of the first to be approved in this class of drugs. In a recent NEJM trial published this year, Chari et al showed that oral selinexor- dexamethasone worked well for  triple class refractory multiple myeloma(MM). We wrote a letter back to the authors published in NEJM few weeks later noticing that  one of the most common grade 3 or 4 adverse event was hyponatremia(<130mmol/l) ( 22%).  In reviewing the prior studies( table below), this is a class effect of selinexor as other trials with the use of this agent had similar rates of hyponatremia ranging from 7%-26%. 
Table: Summary of major trials that led to Grade 3,4 hyponatremia

Phase trial
Incidence of hyponatremia
Intervention
Dose modifications
Reference 
Phase 1 in MM
25%(40mg/m2),
47% (60mg/m2)
Not reported
Not reported
Resolved in most cases
Phase 2 in MM
22%(80mg)
6% got salt tablets,
Dose reduction
Yes, reduced
Resolved in most cases
Phase 1 in solid tumors
13%
Not mentioned
Resolved in most cases
Phase 1 in sarcomas
7%
Not mentioned
Resolved in most cases
Phase 1 in Non Hodgkin lymphomas
10%
Not mentioned
Resolved 

The rates of hyponatremia are higher in the MM studies compared to solid tumor studies.  No workup or cause was found in many of the studies. Another recent study in AML ( phase 1) has close to 70% incidence of hyponatremia. Likely this could be related to the GI effects such as severe nausea leading to an ADH release causing hyponatremia or could this be a direct effect of the mechanism of this agent. Could this drug effect the AQP channels or V2 receptor- not sure as mechanism has not been worked out. A serum osmolarity testing along with urine studies can answer this question. As the drug enters clinical practice, It is very possible that we shall see an even increased incidence given other confounders patients might be on such as thiazides, and or increased free water intake.  Involvement of nephrology consultation in the trials ongoing might be essential to investigate the mechanism of this toxicity. Serum and urine studies would help in assessment of the cause and pathophysiology of the hyponatremia. This will then allow for preventive strategies in further trials and clinical practice. Once out in the real world, it will be more important as lot of our patients could be on thiazides, SSRi and drinking a lot of water and then are given this agent. While most cases the hyponatremia might be asymptomatic, subtle symptoms and appropriate early management can prevent seizures and complications of hyponatremia.
As nephrologists, we need to be aware of this drug as we usually see myeloma patients. 

All Posts

Search This Blog